MDMA/PTSD Australia Study

Australian Study of MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder

This study will evaluate the safety and effectiveness of MDMA-assisted psychotherapy in 12 subjects with chronic, treatment-resistant PTSD. It will compare the effectiveness of two dosages of MDMA in combination with psychotherapy: a full dose of 125mg (with a supplemental 62.5mg) and a low dose of 30mg (with a supplemental 15mg). Seven subjects will be allocated to the full dose condition, with the remaining five to the low dose condition. Subjects in this study will receive two experimental sessions instead of three, enabling us to compare the results with our other studies and helping us to determine whether two or three sessions is more efficient for use in our Phase 3 studies.

Principal Investigators:Dr. Stuart Saker, MBBS, and Fiona MacKenzie, MPsych(Clinical)
Location: In or near Sydney, Australia

This study is still in the protocol development stage.

View the timeline for this study.

This study has not yet been budgeted. We anticipate costs in the range of $250,000, of which MAPS has pledged $50,000 if the Australian research team raises $150,000.